Novo Nordisk Pharmaceuticals (Phils.), Inc.

About Novo Nordisk Pharmaceuticals (Phils.), Inc.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. In the Philippines, Novo Nordisk started its operations in 1976. The Philippine Office obtained approval from the Securities and Exchange Commission to operate as an independent Pharmaceutical Company in June 30, 1999. We offer products and services in the following therapy areas: Diabetes Care. Novo Nordisk offers the broadest portfolio of diabetes products in the industry and an extensive range of user-friendly pen devices for injecting insulin. Human Insulin (Actrapid® 100IU/ml) in Vial, Human Isophane Insulin (Insulatard® 100IU/ml) in Vial and NovoLet® injection device, Human Biphasic Isophane Insulin 30/70 (Mixtard® 30 100 IU/ml) in Vial and NovoLet® injection device, Biphasic Insulin Aspart 30 (NovoMix® 30 100U/ml) in FlexPen™ injection device, Insulin Aspart (NovoRapid®) in FlexPen™ injection device, Insulin Detemir (Levemir®) in FlexPen™ injection device, Repaglinide (NovoNorm®) tablets in 500mcg, 1mg and 2mg, NovoFine® 30G (0.3x8mm) insulin needle. Coagulation management. Novo Nordisk has developed NovoSeven®, a recombinant Factor Vlla for treatment of bleeds in haemophilia A and B patients with inhibitors. This recombinant protein is expressed from cloned human FVII genes in baby hamster kidney cells. No material of human origin is used in the production process or in the final product. We are currently offering Recombinant Coagulation Factor VIIa (NovoSeven® 1.2mg/ml). Growth hormone therapy. Human Somatropin (Norditropin® SimpleXx® 5mg/1.5ml) NordiPen® 5. Injection device. Hormone replacement therapy (HRT). Estradiol (Vagifem®) vaginal tablets, Estradiol (Estrofem® 2mg) tablets, Estradiol Norethisterone Acetate (Kliogest®) tablets.